# Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)

> **NCT04858867** · NA · UNKNOWN · sponsor: **Leiden University Medical Center** · enrollment: 12 (estimated)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **RADIATION:** rhTSH-stimulated I-124 dosimetry
- **RADIATION:** Intra-therapeutic I-131 dosimetry

## Key facts

- **NCT ID:** NCT04858867
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-10
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858867, "Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04858867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*